[
  {
    "ts": null,
    "headline": "Biogen Strengthens Pipeline With Stoke Therapeutic's Dravet Syndrome Candidate Via Multi-Million Dollar Deal",
    "summary": "On Tuesday, Biogen Inc. (NASDAQ:BIIB) and Stoke Therapeutics, Inc. (NASDAQ:STOK) collaborated to develop and commercialize zorevunersen for Dravet syndrome in all territories outside the United States, Canada, and Mexico. Zorevunersen is an investigational antisense oligonucleotide (ASO) that targets the SCN1A gene, the underlying cause of most cases of Dravet syndrome. Stoke recently announced plans to initiate a global Phase 3 registrational study of zorevunersen (EMPEROR) following the alignm",
    "url": "https://finnhub.io/api/news?id=ce97f1c65ffe3f0d13d0ff332303495049d386f281b5106279962a90201d05d7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1739903543,
      "headline": "Biogen Strengthens Pipeline With Stoke Therapeutic's Dravet Syndrome Candidate Via Multi-Million Dollar Deal",
      "id": 133191262,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "On Tuesday, Biogen Inc. (NASDAQ:BIIB) and Stoke Therapeutics, Inc. (NASDAQ:STOK) collaborated to develop and commercialize zorevunersen for Dravet syndrome in all territories outside the United States, Canada, and Mexico. Zorevunersen is an investigational antisense oligonucleotide (ASO) that targets the SCN1A gene, the underlying cause of most cases of Dravet syndrome. Stoke recently announced plans to initiate a global Phase 3 registrational study of zorevunersen (EMPEROR) following the alignm",
      "url": "https://finnhub.io/api/news?id=ce97f1c65ffe3f0d13d0ff332303495049d386f281b5106279962a90201d05d7"
    }
  },
  {
    "ts": null,
    "headline": "Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments",
    "summary": "Stoke retains exclusive rights for zorevunersen in the United States, Canada, and Mexico; Biogen receives exclusive rest of world commercialization rights Collaboration broadens Biogen’s rare disease pipeline and leverages global expertise commercializing high-value, disease-modifying medicines for rare genetic diseases Pivotal Phase 3 EMPEROR study of zorevunersen on track to initiate in Q2 2025 with an anticipated readout in 2H 2027 Stoke to receive $165M upfront, shared development costs and",
    "url": "https://finnhub.io/api/news?id=43a027ab7f24f3bccd08f831bc1120e1ca690e911b39501a3d3155e32b81f57d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1739883600,
      "headline": "Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments",
      "id": 133191263,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Stoke retains exclusive rights for zorevunersen in the United States, Canada, and Mexico; Biogen receives exclusive rest of world commercialization rights Collaboration broadens Biogen’s rare disease pipeline and leverages global expertise commercializing high-value, disease-modifying medicines for rare genetic diseases Pivotal Phase 3 EMPEROR study of zorevunersen on track to initiate in Q2 2025 with an anticipated readout in 2H 2027 Stoke to receive $165M upfront, shared development costs and",
      "url": "https://finnhub.io/api/news?id=43a027ab7f24f3bccd08f831bc1120e1ca690e911b39501a3d3155e32b81f57d"
    }
  },
  {
    "ts": null,
    "headline": "Biogen buys rights to Stoke’s rare epilepsy drug",
    "summary": "In exchange for $165 million, Biogen now has access to zorevunersen, a potential first-of-its-kind treatment for Dravet syndrome.",
    "url": "https://finnhub.io/api/news?id=0c3032831df0bcbb79d3028c22cfba4c114172a398d92cea33daa1200a0d6bc2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1739881500,
      "headline": "Biogen buys rights to Stoke’s rare epilepsy drug",
      "id": 133191264,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "In exchange for $165 million, Biogen now has access to zorevunersen, a potential first-of-its-kind treatment for Dravet syndrome.",
      "url": "https://finnhub.io/api/news?id=0c3032831df0bcbb79d3028c22cfba4c114172a398d92cea33daa1200a0d6bc2"
    }
  },
  {
    "ts": null,
    "headline": "Stoke Therapeutics and Biogen in pact for treatment for severe form of childhood epilepsy",
    "summary": "Stoke Therapeutics and Biogen in pact for treatment for severe form of childhood epilepsy",
    "url": "https://finnhub.io/api/news?id=3aa0b6211cbcd1908b35ad13e3417fb53a5530db15b1674f8402daf1192a5a67",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1739871900,
      "headline": "Stoke Therapeutics and Biogen in pact for treatment for severe form of childhood epilepsy",
      "id": 132816738,
      "image": "",
      "related": "BIIB",
      "source": "MarketWatch",
      "summary": "Stoke Therapeutics and Biogen in pact for treatment for severe form of childhood epilepsy",
      "url": "https://finnhub.io/api/news?id=3aa0b6211cbcd1908b35ad13e3417fb53a5530db15b1674f8402daf1192a5a67"
    }
  },
  {
    "ts": null,
    "headline": "Biogen, Stoke Therapeutics Set Dravet Syndrome Collaboration",
    "summary": "Biogen, Stoke Therapeutics Set Dravet Syndrome Collaboration",
    "url": "https://finnhub.io/api/news?id=c06c3437be5573b8b80b4a3b0cf24dc5901feba75524204d1702df7a2be24c5e",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1739868900,
      "headline": "Biogen, Stoke Therapeutics Set Dravet Syndrome Collaboration",
      "id": 132816739,
      "image": "",
      "related": "BIIB",
      "source": "MarketWatch",
      "summary": "Biogen, Stoke Therapeutics Set Dravet Syndrome Collaboration",
      "url": "https://finnhub.io/api/news?id=c06c3437be5573b8b80b4a3b0cf24dc5901feba75524204d1702df7a2be24c5e"
    }
  }
]